administration. These studies suggest that an understanding of the regulation of this enzyme activity and of its intracellular abundance could shed new light on the function of the enzyme and of prostaglandins. Such studies would be greatly aided by the production of antibodies against the enzyme. Questions about the distribution, abundance and turnover of the enzyme under various conditions could be examined by measuring the quantities of the enzyme protein and with immunocytochemical techniques. The extent of structural analogy of the enzyme from different sources could also be probed by site-specific monoclonal antibodies. In this report, we describe our success in obtaining three monoclonal antibodies to the enzyme, each of which inhibits the enzyme to a different degree, suggesting that these monoclonal antibodies all interact with the enzyme near the active site, but in different
INTRODUCTION
NAD+-dependent 1 5-hydroxyprostaglandin dehydrogenase (15-OH-PGDH) catalyses NADI-linked oxidation of the 15- hydroxy group of prostaglandins to a 15-oxo function [1] . It has been considered to be the key enzyme that controls the biological activity of prostaglandins, since 15-oxo-prostaglandins possess little activity [2] . The enzyme has been purified to homogeneity from human placenta [3] [4] [5] , rabbit lung [6] and pig kidney [7] and found to be a dimer of subunit Mr of 25 000-29 000. Although the enzyme was found to be ubiquitous in mammalian tissues [8, 9] , the extent of structural analogy of the enzyme from different tissues and species remains unknown. The activity of the enzyme was shown to alter during development [10] , pregnancy [11] , hormone [12] and anti-inflammatory-steroid [13] administration. These studies suggest that an understanding of the regulation of this enzyme activity and of its intracellular abundance could shed new light on the function of the enzyme and of prostaglandins. Such [9] . Other supplies for monoclonal antibody production were as described by Shen & Tai [14] . Human 
SDS/PAGE and immunoblotting of 15-OH-PGDH
Proteins were fractionated by SDS/PAGE according to the method of Laemmli [16] . Electrophoretic transfer of proteins from polyacrylamide gel to nitrocellulose paper was performed according to the method of Towbin et al. [17] . Visualization of antigenic protein was performed according to Knecht & Dimond [18] .
RESULTS AND DISCUSSION
Several stable monoclonal cell lines were obtained from a single mouse immunized with the purified human placental 15- 
OH-PGDH. Three of these monoclones (PGDH-1, -2 and -3)
were found to produce IgG2b, which inhibited the enzyme activity of 15-OH-PGDH as shown in Fig. 1 . PGDH-1 antibody showed the highest inhibitory activity, giving a maximum of 60 % inhibition, whereas PGDH-2 and PGDH-3 antibodies gave 50 % and 35 % inhibition respectively. The PGDH-l antibody did not only inhibit human placental 15-OH-PGDH activity, but it also inhibited 15-OH-PGDH activity from rabbit lung, pig kidney and pig lung as shown in Fig. 2 . However, no complete inhibition can be seen with any of the three monoclonal antibodies, indicating partial blockade of the active site of the enzyme. Differential inhibition of the enzyme activity from different sources also suggests that the antibody cross-reacts with the enzyme near the active site to different degrees, reflecting structural differences in the binding domain of the enzyme from different sources.
In addition to inhibiting the enzyme activity, the IgG2b produced by these monoclones also recognized the 15-OH-PGDH from both the purified and the crude placental enzyme preparation, as shown in the SDS/PAGE immunoblotting studies (Fig. 3) . A distinct band of Mr28000 was observed in homogeneous, partially purified and crude cytosol preparations.
As well as the M,-28000 band, the antibodies also recognized a band of Mr 56000 in the crude cytosol fraction. This band could be due to part of the native enzyme that was not completely dissociated into subunits. A protein band of similar Mr has been reported on SDS/PAGE analysis by Jarabak & Watkins [4] and Tanaka et al. [5] in their isolated human placental 15-OH-PGDH.
Inhibition of 1 5-OH-PGDH activity by monoclonal antibodies can be prevented by prior addition of NADI but not of NADP+ or PGE2 to the enzyme preparation, as shown in Fig. 4 from inhibition suggests that the antibody binds specifically to the coenzyme-binding domain but not to the substrate-binding site. This is also evident from the kinetic studies, in which inhibition of the enzyme activity by increasing concentrations of antibody was determined at various concentrations of NADI (Fig. 5) or PGE2 (Fig. 6 ). Increased concentrations of antibody altered the apparent Km for NAD+ but not that for PGE2, further supporting the notion that the antibody binds to the coenzymebinding site and prevents NAD+ from interacting effectively with the enzyme. Since studies on the kinetic order of addition of coenzyme and PGE2 to1 5-OH-PGDH indicated that NADI was the first to bind to the enzyme before oxidation of PGE2 can occur [19] , antibody apparently blocked the binding of NADI to the active site and prevented the subsequent oxidation of PGE2.
In conclusion, these monoclonal antibodies should prove valuable for probing the structure of the NADI-binding site of 1 5-OH-PGDH. Furthermore, the availability of these antibodies should be also useful for studying the distribution and abundance of the immunoreactive enzyme in different tissues and species by immunocytochemical techniques and for molecular cloning of the gene by immunoscreening of the cDNA expression library. Vol. 267 We are indebted to Ms. Jean Cavenee for typing the manuscript. This study was supported in part by a grant from the National Institute of Health (GM-30380).
